EP3964504A4 - Aminopyrimidinverbindung, herstellungsverfahren dafür und verwendung davon - Google Patents

Aminopyrimidinverbindung, herstellungsverfahren dafür und verwendung davon Download PDF

Info

Publication number
EP3964504A4
EP3964504A4 EP20798155.6A EP20798155A EP3964504A4 EP 3964504 A4 EP3964504 A4 EP 3964504A4 EP 20798155 A EP20798155 A EP 20798155A EP 3964504 A4 EP3964504 A4 EP 3964504A4
Authority
EP
European Patent Office
Prior art keywords
preparation
benzothiophene compound
benzothiophene
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20798155.6A
Other languages
English (en)
French (fr)
Other versions
EP3964504A1 (de
Inventor
Jinming Liu
Yun Ren
Qiang Tian
Hongmei SONG
Tongtong XUE
Jingyi Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of EP3964504A1 publication Critical patent/EP3964504A1/de
Publication of EP3964504A4 publication Critical patent/EP3964504A4/de
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP20798155.6A 2019-04-30 2020-04-20 Aminopyrimidinverbindung, herstellungsverfahren dafür und verwendung davon Pending EP3964504A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910359616 2019-04-30
PCT/CN2020/085525 WO2020221038A1 (zh) 2019-04-30 2020-04-20 苯并噻吩类化合物及其制备方法和用途

Publications (2)

Publication Number Publication Date
EP3964504A1 EP3964504A1 (de) 2022-03-09
EP3964504A4 true EP3964504A4 (de) 2022-12-28

Family

ID=73028761

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20798155.6A Pending EP3964504A4 (de) 2019-04-30 2020-04-20 Aminopyrimidinverbindung, herstellungsverfahren dafür und verwendung davon

Country Status (6)

Country Link
US (1) US12269816B2 (de)
EP (1) EP3964504A4 (de)
JP (1) JP7531508B2 (de)
KR (1) KR102885020B1 (de)
CN (2) CN118108716A (de)
WO (1) WO2020221038A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3149482A1 (en) 2019-08-02 2021-02-11 Mersana Therapeutics, Inc. Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer
WO2021113679A1 (en) * 2019-12-06 2021-06-10 Mersana Therapeutics, Inc. Dimeric compounds as sting agonists
WO2021202984A1 (en) 2020-04-02 2021-10-07 Mersana Therapeutics, Inc. Antibody drug conjugates comprising sting agonists
WO2021206158A1 (ja) 2020-04-10 2021-10-14 小野薬品工業株式会社 がん治療方法
CN115772154B (zh) * 2021-09-08 2024-04-30 上海交通大学 一类含有氘取代的苯并噻吩类衍生物及其制备与用途
CN119212984A (zh) * 2022-04-25 2024-12-27 密歇根大学董事会 Sting激动剂、制剂及其用途
WO2024032782A1 (en) * 2022-08-12 2024-02-15 Jacobio Pharmaceuticals Co.Ltd. Vaccine adjuvants and uses thereof
CN115950995B (zh) * 2022-12-02 2026-01-13 中国石油大学(北京) 一种分离石油油品中噻吩类化合物的方法及其应用
WO2025096584A1 (en) * 2023-10-30 2025-05-08 The Regents Of The University Of Michigan Sting agonists, compositions, and uses thereof
CN119219600B (zh) * 2024-08-06 2025-09-26 国家纳米科学中心 一种sting激动剂msa-2的水溶性前药化合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019069275A1 (en) * 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited STING AGONIST ADMINISTRATION METHODS

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
UA92450C2 (ru) * 2003-01-14 2010-11-10 Арена Фармасьютикалз, Инк. 1,2,3-тризамещенные арильные и гетероарильные производные как модуляторы метаболизма, профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия
BRPI0815096A2 (pt) 2007-07-18 2015-07-14 Janssen Pharmaceutica Nv Sulfonamidas como moduladores de trpm8
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited タンパク質調節物質として有用な複素環アミド
US10414747B2 (en) 2016-10-04 2019-09-17 Merck Sharp & Dohme Corp. Benzo[b]thiophene compounds as sting agonists
JP2018067423A (ja) 2016-10-18 2018-04-26 パナソニックIpマネジメント株式会社 グリップセンサ
PE20200696A1 (es) * 2017-06-22 2020-06-16 Curadev Pharma Ltd Moduladores de moleculas pequenas de sting humana
JP2020524718A (ja) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドCuradev Pharma Limited ヒトstingの複素環式小分子調節因子
US20200138827A1 (en) 2017-06-22 2020-05-07 Curadev Pharma Limited Small molecule modulators of human sting
JP2019027857A (ja) 2017-07-27 2019-02-21 トヨタ自動車株式会社 ネジゲージ取り外し冶具
US11285131B2 (en) 2017-08-04 2022-03-29 Merck Sharp & Dohme Corp. Benzo[b]thiophene STING agonists for cancer treatment
US11312772B2 (en) 2017-08-04 2022-04-26 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment
US10793557B2 (en) * 2018-04-03 2020-10-06 Merck Sharp & Dohme Corp. Sting agonist compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019069275A1 (en) * 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited STING AGONIST ADMINISTRATION METHODS

Also Published As

Publication number Publication date
US20220162199A1 (en) 2022-05-26
WO2020221038A1 (zh) 2020-11-05
JP7531508B2 (ja) 2024-08-09
JP2022530936A (ja) 2022-07-05
CN113518776B (zh) 2024-03-26
CN118108716A (zh) 2024-05-31
CN113518776A (zh) 2021-10-19
US12269816B2 (en) 2025-04-08
KR20220004013A (ko) 2022-01-11
EP3964504A1 (de) 2022-03-09
KR102885020B1 (ko) 2025-11-11

Similar Documents

Publication Publication Date Title
EP4011886A4 (de) Tetrazyklische verbindung, herstellungsverfahren dafür und verwendung da
EP3964504A4 (de) Aminopyrimidinverbindung, herstellungsverfahren dafür und verwendung davon
EP3816150A4 (de) M-diamid-verbindung sowie herstellungsverfahren dafür und verwendung davon
EP3889154A4 (de) Zwischenprodukt einer heterozyklischen verbindung, verfahren zu ihrer herstellung und ihre verwendung
EP4043464A4 (de) Kondensierte pyridonverbindung, herstellungsverfahren dafür und verwendung davon
MA54471A (fr) Composé agoniste de récepteur thrb, son procédé de préparation et son utilisation
EP4194449A4 (de) Heterocyclische verbindung, herstellungsverfahren dafür und verwendung davon
EP4053118A4 (de) Substituierte heterocyclische kondensierte cyclische verbindung, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
EP3778579A4 (de) Aromatische verbindung sowie herstellungsverfahren dafür und verwendung davon
EP3967687A4 (de) Substituiertes phenylpropenylpyridinderivat und herstellungsverfahren dafür und medizinische verwendung davon
EP3517535A4 (de) Alkynyl-substituierte heterocyclische verbindung, herstellungsverfahren dafür und medizinische verwendung davon
EP3660019A4 (de) Verbindung sowie ihre herstellung und verwendung
EP4006024A4 (de) Heterozyklische amidverbindung, herstellungsverfahren dafür und verwendung davon
EP3640248A4 (de) Aminopyrimidinverbindung, herstellungsverfahren dafür und verwendung davon
EP3828168A4 (de) Quaternäre ammoniumverbindung und verfahren zu ihrer herstellung und verwendung
EP3828169A4 (de) Dikationsverbindung, herstellungsverfahren dafür und verwendung davon
EP3964518A4 (de) Cd73-inhibitor, herstellungsverfahren dafür und anwendungen davon
EP3556761A4 (de) Pyrrolo-aromatische heterocyclische verbindung, herstellungsverfahren dafür und medizinische verwendung davon
EP3998265A4 (de) Ret-selektiver inhibitor, herstellungsverfahren dafür und verwendung davon
EP4137483A4 (de) Heterocyclische benzolitrierverbindung, herstellungsverfahren dafür und verwendung davon
EP4063363A4 (de) Pyrazolheteroarylderivat, herstellungsverfahren dafür und medizinische verwendung davon
EP3967682A4 (de) Bisheterocyclische carbonyl-substituierte dihydropyrazolverbindung, herstellungsverfahren dafür und pharmazeutische verwendung davon
EP4119546A4 (de) Bifunktionelle verbindung, herstellungsverfahren dafür und verwendung davon
EP4063453A4 (de) Polypropylenzusammensetzung, herstellungsverfahren dafür und verwendung davon
EP3858833A4 (de) Aminonordekanderivat und herstellungsverfahren dafür und anwendung davon

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210830

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20221125

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20221121BHEP

Ipc: A61K 31/4155 20060101ALI20221121BHEP

Ipc: A61K 31/381 20060101ALI20221121BHEP

Ipc: C07D 409/14 20060101ALI20221121BHEP

Ipc: C07D 333/64 20060101AFI20221121BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230428

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20260216